CFDE Data Portal | Search CYP39A1

	Label	Description
	CYP39A1 Gene (Entity type)	ENSG00000146233 - cytochrome P450 family 39 subfamily A member 1
	CYP39A1 associations Collection (Entity type)	Associations for CYP39A1_associations
	CYP39A1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE216043 7 V 9 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE135514 8 V 7 DASATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE228727 2 V 1 DAPAGLIFLOZIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 1 V 3 PROGESTERONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 ivermectin prostate gland 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

CYP39A1

ENSG00000146233 - cytochrome P450 family 39 subfamily A member 1

CYP39A1 associations

Associations for CYP39A1_associations

CYP39A1 associations.tsv

A file from IDG as part of the Harmonizome project

GSE216043 7 V 9 CISPLATIN HUMAN DN

A Gene Set from LINCS

GSE135514 8 V 7 DASATINIB HUMAN DN

A Gene Set from LINCS

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

A Gene Set from LINCS

GSE228727 2 V 1 DAPAGLIFLOZIN MOUSE UP

A Gene Set from LINCS

GSE220806 1 V 3 PROGESTERONE HUMAN UP

A Gene Set from LINCS

GSE169356 ivermectin prostate gland 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.